Cargando…
A Case Series of Survival Outcomes in Patients with Advanced-stage IIIb/IV Non-small-cell Lung Cancer Treated with HangAm-Plus
BACKGROUND AND OBJECTIVES: Non-small-cell lung cancer (NSCLC) represents approximately 80% of all lung cancers. Unfortunately, at their time of diagnosis, most patients have advanced to unresectable disease with a very poor prognosis. The oriental herbal medicine HangAm-Plus(HAP) has been developed...
Autores principales: | Bang, Sun-Hwi, Yoon, Jeung-Won, Cho, Chong-Kwan, Shin, Ji-Eun, Lee, Yeon-Weol, Yoo, Hwa-Seung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
KOREAN PHARMACOPUNCTURE INSTITUTE
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331932/ https://www.ncbi.nlm.nih.gov/pubmed/25780640 http://dx.doi.org/10.3831/KPI.2012.15.2.031 |
Ejemplares similares
-
Prospective Analysis on Survival Outcomes of Nonsmall Cell Lung Cancer Stages over Ⅲb Treated with HangAm-Dan
por: JEONG, Tae-Young, et al.
Publicado: (2010) -
Inhibition of lung cancer growth by HangAmDan-B is mediated by macrophage activation to M1 subtype
por: Park, Hye-Rin, et al.
Publicado: (2017) -
Wheel Balanced Cancer Therapy for Longer Than 21 Days Can Have a Positive Effect on the Survival of Patients with Stage IV Cancer
por: Jeon, Hyung-Joon, et al.
Publicado: (2015) -
Inhibitory Effects of HangAmDan-B1 (HAD-B1) Combined With Afatinib on H1975 Lung Cancer Cell–Bearing Mice
por: Kang, Hwa Jeong, et al.
Publicado: (2019) -
Identification of Target Genes Involved in the Antiproliferative Effect of Enzyme-Modified Ginseng Extract in HepG2 Hepatocarcinoma Cell
por: Jang, Sung-Il, et al.
Publicado: (2013)